A pilot trial for severe, refractory systemic autoimmune disease with stem cell transplantation

Chinese Medical Sciences Journal

Volumn 20, Issue 3, 2005, Pages 159-165

  Leng, Xiao Mei ^a   Zhao, Yan ^a   Zhou, Dao Bing ^a   Situ, Huifen ^a   Li, Tai Sheng ^a   Shen, Ti ^a   Zhao, Yong Qiang ^a   Zeng, Xiao Feng ^a   Zhang, Feng Chun ^a   Dong, Yi ^a   Tang, Fu Lin ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Hemopoietic stem cell transplantation; Systemic autoimmune disease; Therapeutics

Indexed keywords

ACICLOVIR; CD34 ANTIGEN; CEPHALOSPORIN; CHLORHEXIDINE; CHLORTETRACYCLINE; CYCLOPHOSPHAMIDE; FLUCONAZOLE; GANCICLOVIR; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; NORFLOXACIN; SULFAMETHOXAZOLE;

ALOPECIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CD34 SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DYSFUNCTION; MALE; MORTALITY; NAUSEA; PAIN; PILOT STUDY; PNEUMONIA; RECURRENT DISEASE; RELAPSE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANTIGENS, CD34; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PILOT PROJECTS; RECURRENCE; SJOGREN'S SYNDROME; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 26944463476     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Marai I, Levi Y, Shoenfeld Y. Morbidity and mortality in systemic lupus erythematosus. Harefuah 2001;140:1177-80, 1229, 1228.
2. Lindqvist E, Saxne T, Geborek P, et al. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 2002;61:1055-9.
3. Anstey NM, Bastian I, Dunckley H, et al. Systemic lupus erythematosus in Australian aborigines: high prevalence, morbidity and mortality. Aust N Z J Med 1993;23:646-51.
4. Cook RJ, Gladman DD, Pericak D, et al. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J Rheumatol 2000;27:1892-5.
5. Adams DD, Knight JG. Principles of autoimmune disease: pathogenesis, genetics and specific immunotherapy. J Clin Lab Immunol 2003;52:1-22.
6. Tuscano JM, Harris GS, Tedder TF. B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications. Autoimmun Rev 2003;2:101-8.
7. Stassi G, Di Felice V, Todaro M, et al. Involvement of Fas/FasL system in the pathogenesis of autoimmune diseases and Wilson's disease. Arch Immunol Ther Exp (Warsz) 1999;47:129-33.
8. van Bekkum DW. Stem cell transplantation in experimental models of autoimmune disease. J Clin Immunol 2000;20:10-6.
9. Ikehara S, Good RA, Nakamura T, et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci U S A 1985;82:2483-7.
10. Adachi Y, Inaba M, Amoh Y, et al. Effect of bone marrow transplantation on antiphospholipid antibody syndrome in murine lupus mice. Immunobiology 1995;192:218-30.
11. Euler HH, Marmont AM, Bacigalupo A, et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996;88:3621-5.
12. Anderson KC, Ritz J, Takvorian T, et al. Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood 1987;69:597-604.
13. Novitzky N, Davison GM, Hale G, et al. Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome. Transplantation 2002;74:1551-9.
14. Marmont AM, van Lint MT, Gualandi F, et al. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus 1997;6:545-8.
15. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Br J Rheumatol 1997;36:390-2.
16. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
17. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
18. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
19. Medsger TA Jr, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
20. Sutcliffe N, Stoll T, Pyke S, et al. Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjogren's syndrome (SS), and primary SS. J Rheumatol 1998;25:63-8.
21. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
22. Leng XM, Zhao Y, Zhou DB, et al. Study of treatment of refractory rheumatoid arthritis with autologous peripheral blood stem cell transplantation. Zhonghua Yi Xue Za Zhi 2002;82:748-51.
23. Traynor AE, Ban WG, Rosa RM, et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 2002;46:2917-23.
24. Tyndall A, Passweg J, Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann Rheum Dis 2001;60:702-7.
25. Pavletic SZ, Klassen LW, Pope R, et al. Treatment of relapse after autologous blood stem cell transplantation for severe rheumatoid arthritis. J Rheumatol Suppl 2001;64:28-31.
26. Matulis M, High KP. Immune reconstitution after hematopoietic stem-cell transplantation and its influence on respiratory infections. Semin Respir Infect 2002;17:130-9.
27. Reimer P, Kunzmann V, Wilhelm M, et al. Cellular and humoral immune reconstitution after autologous peripheral blood stem cell transplantation (PBSCT). Ann Hematol 2003;82:263-70.
28. Fu YW, Zhu P, Zhao XW, et al. The variation of T-cell clonal repertoire in patients with systemic lupus erythematosus (SLE) following autologous peripheral blood hematopoietic stem cell transplantation. Zhonghua Yi Xue Za Zhi 2003;83:1648-52.
29. Alarcon GS, McGwin G Jr, Petri M, et al. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 2002;11:95-101.
30. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:527-39.